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NOT PRECEDENTIAL 
 
 UNITED STATES COURT OF APPEALS 
 FOR THE THIRD CIRCUIT 
___________ 
 
 No. 09-3979 
___________ 
 
In Re: DIET DRUGS 
(PHENTERMINE/FENFLURAMINE/DEXFENFLURAMINE) 
PRODUCT LIABILITY LITIGATION 
 
        Rose Sellers,  Appellant 
_______________________ 
 
 On Appeal from the United States District Court 
for the Eastern District of Pennsylvania 
 D.C. Civil Action No. 99-cv-20593 
 (Honorable Harvey Bartle III) 
______________ 
 
 Submitted Pursuant to Third Circuit LAR 34.1(a) 
 November 1, 2010 
 Before:  SCIRICA, STAPLETON and ROTH, Circuit Judges. 
 
 (Filed January 21, 2011) 
_________________ 
 
 OPINION OF THE COURT 
_________________ 
 
SCIRICA, Circuit Judge. 
 
 Rose Sellers appeals the District Court’s affirmance of an arbitrator’s denial of 
additional benefits under the Diet Drug Nationwide Class Settlement Agreement relating 
to ingestion of the diet drugs fenfluramine (Pondimin) and dexefenfluramine (Redux).  
We will affirm. 
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I. 
 Sellers, a class member, sought matrix compensation benefits from the American 
Home Products Settlement Trust, created to resolve legal claims relating to the sale, 
distribution, and use of the diet drugs.
1
  To be eligible to receive matrix benefits, the 
settlement agreement requires a class member to demonstrate he or she suffers from 
certain medical conditions, and that he or she used the diet drugs.  Moreover, the 
agreement sets forth how these two conditions must be proven. 
 Sellers initially registered for benefits on February 17, 2000, under the 
“Accelerated Implementation Option” set forth in the settlement agreement, and 
administered through a form referred to as the pink form.  The pink form provides several 
ways for claimants to provide information about their receipt of diet drugs.  A claimant 
could provide, the “pharmacy name, address and telephone number” and the dispensing 
records, including “the medicine’s name, quantity, frequency, dosage, and number of 
refills prescribed, prescribing physicians [sic] name, assigned prescription number, 
original fill date and each subsequent refill date.”  If the drugs were “dispensed directly 
by a physician or weight loss clinic, or the pharmacy record(s) is unobtainable,” a 
claimant could “state the name of each physician who prescribed the diet drug, and the 
address and telephone number of that physician,” along with medical records “reflecting 
the prescription and/or dispensing of the diet drugs.”  Under this option, a claimant could 
                                                 
1
American Home Products is the successor in interest to Wyeth Corporation, which 
produced the drugs.   
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authorize the claims administrator to obtain copies of the records in the event the 
claimant did not have or did not wish to obtain them.  Finally, “[i]f and only if the 
pharmacy record(s) or medical record(s) are unobtainable,” a claimant could provide a 
“Declaration of Prescribing Physician or Dispensing Pharmacy.”  
 On her pink form, Sellers provided incomplete answers regarding the source from 
which she obtained diet drugs and the physician who prescribed or dispensed the drugs.  
Moreover, she failed to provide adequate medical records, to complete the authorization 
for the trust to obtain her medical records, or to provide a declaration from her 
prescribing physician or the dispensing pharmacy as required by the form.  
The trust issued a deficiency letter on November 17, 2000, advising Sellers it 
required copies of her medical and prescription records.  In response to the November 
2000 deficiency letter, Sellers returned a medical records authorization, but failed to 
provide specific information regarding her prescriber or the dispensing entity.  The trust 
once again sent letters in December of 2000 and January of 2001 notifying Sellers of this 
deficiency.  Sellers returned the letter and another medical records authorization without 
providing specific information regarding her prescriber or the dispensing entity.  Despite 
these deficiencies, the trust notified Sellers in August of 2001 she was eligible to receive 
certain benefits under the settlement agreement—a transthoracic echocardiogram and 
accompanying physician visit, and a refund for a portion of the cost of the diet drugs.   
 Subsequently, in November of 2001, Sellers provided an additional statement 
concerning her receipt and ingestion of the drugs, which stated  “[t]he drugs were sent to 
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me in the mail after I went to a Fen Phen diet clinic in the Speedway Shopping Center in 
Indianapolis, Indiana,” as the source of the drugs.  She did not provide information about 
her prescriber.  In response, the trust again requested the names and addresses of 
physicians or clinics who dispensed the drugs.  Sellers mailed a response stating “I went 
to a clinic (I think Physician Weight Loss Center) at Speedway Shopping Center at 5620 
Crawfordsville Road, Indianapolis, IN.  They sent me the prescription through the mail.”   
The trust issued a deficiency notice on April 5, 2004, explaining that information and 
records demonstrating duration of her use of the drugs, and required for processing of the 
pink form, were incomplete.  In April 2004, Sellers responded, providing vague 
information and prompting the trust to issue a final deficiency notice on June 17, 2004.    
Sellers responded to the final deficiency notice with incomplete information about the 
dispenser, but added she “took Phen-Fen for three to four months.” 
Notwithstanding her failure to provide adequate information for the receipt of 
benefits under the accelerated implementation option, Sellers submitted a claim for 
matrix compensation benefits in November 2004 based on the results of her physician 
examination showing she had moderate mitral regurgitation and an ejection fraction of 
50-60%.  To apply for matrix benefits, she submitted the trust’s green form. 
 The settlement agreement requires, among other things, proof of diet drug 
prescription and dispensing as a prerequisite for claimants to establish eligibility for 
matrix compensation benefits: 
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[E]ach Class Member must submit documentary proof . . . of the period of 
time for which the Diet Drugs . . . were prescribed and dispensed to the 
Diet Drug Recipient who is the subject of the Claim.  This proof must 
include one of the following: 
 
(1) If the diet drug was dispensed by a pharmacy, the identity of each 
pharmacy that dispensed the Diet Drugs to the Diet Drug Recipient,  
including its name, address, and telephone number, and a copy of the 
prescription  dispensing record (s) from each pharmacy, which should 
include the medication name, quantity, frequency, dosage and number of 
refills prescribed, prescribing physician’s name, assigned prescription 
number, original fill date and each subsequent refill date; or,  
 
(2) If the diet drug was dispensed directly by a physician or weight loss 
clinic, or the pharmacy record(s) is unobtainable, the identity of each 
prescribing physician, including the prescribing physician’s name, address, 
and telephone number and a copy of the medial record(s) prescribing or 
dispensing the diet drug(s).  the medical record(s) must include records 
which identify the Diet Drug Recipient, the Diet Drug name, the date(s) 
prescribed, the dosage, and duration the drug was prescribed or dispensed; 
 
(3) If the pharmacy records and medical records are unobtainable, an 
affidavit under penalty of perjury from the prescribing physician or 
dispensing pharmacy identifying the Diet Drug Recipient, the drug(s) 
prescribed or dispensed, the date(s), quantity, frequency, dosage and 
number of prescriptions or refills of the Diet Drug(s). 
 
But Sellers substantiated her claim on January 12, 2006, using only two affidavits 
concerning her use of the diet drugs—one from her husband, and one from her sister-in-
law.  The affidavits failed to specify the  medications ingested, the dates, quantity, 
frequency, and number of refills.  Moreover, she submitted no records of prescription, 
dispensing, or payment. 
 The trust denied matrix benefits on August 14, 2006, because of the failure to 
provide adequate documentation supporting Sellers’ receipt and ingestion of diet drugs.   
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In response, on August 28, 2006, Sellers contested the denial of benefits.  The trust issued 
a final denial of matrix benefits on September 25, 2006, explaining Sellers failed to 
adequately establish usage of diet drugs in accordance with the settlement agreement. 
 Sellers appealed the trust’s determination, and the appeal was referred to 
arbitration.  Her appeal was denied by the arbitrator on March 20, 2009.  Sellers appealed 
the arbitrator’s decision to the District Court on April 16, 2009.  The District Court 
affirmed the arbitrator’s report on September 10, 2009.  Sellers timely filed this appeal. 
II.
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 Sellers’ principal arguments on appeal are that she provided sufficient evidence of 
diet drug ingestion pursuant to the controlling settlement forms, and that AHP breached a 
contract with her because it refused to accept her evidence of diet drug ingestion in 
evaluating her application for matrix benefits.
3
  The settlement agreement requires 
specific types of proof about receipt of diet drugs.  We have explained in relation to this 
                                                 
2
We have jurisdiction under 28 U.S.C. § 1291.  We review a district court’s order 
affirming an arbitration award for abuse of discretion.  In re Cendant Corp. Prides Litig., 
233 F.3d 188, 192 (3d Cir. 2000).  We review findings of fact for clear error, and legal 
questions de novo.  See China Minmetals Materials Imp. & Exp. Co. v. ChiMei Corp.,  
334 F.3d 274, 278 (3d Cir. 2003). 
3
Sellers also brings an equitable estoppel claim and a claim under the doctrine of laches.  
These claims are unpersuasive.  An equitable estoppel claim will lie only when a party 
intentionally or negligently  “induce[d] another to believe certain facts to exist and the 
other party rightfully relie[d] and act[ed] on such belief to its detriment.”  Kirleis v. 
Dickie, McCamey & Chilcote, P.C., 560 F.3d 156, 165 (3d Cir. 2009).  There is no 
evidence of misrepresentation or detrimental reliance in the record.  Sellers’ doctrine of 
laches claim is also unavailing.  Laches is an affirmative defense that requires a 
defendant be prejudiced as a result of a plaintiff’s inexcusable delay in bringing suit.  
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lengthy litigation that “the District Court’s prior decisions are instructive.”  In re Diet 
Drugs Prods. Liab. Litig. (Patterson), 543 F.3d 179, 185 (3d Cir. 2008).  The district 
court has consistently required claimants to comply with the plain terms of the agreement 
specifying required proof of receipt of diet drugs.  See, e.g., In re Diet Drugs Prods. Liab. 
Litig. (Brown), No. 99-20593, 2004 U.S. Dist LEXIS 4433 (E.D. Pa. Feb. 13, 2004).  
Sellers does not dispute that she provided neither the records specified in the settlement 
agreement, nor an affidavit from the prescriber or dispenser.  Accordingly, the District 
Court did not err when it concluded Sellers failed to provide adequate proof of diet drug 
ingestion under the settlement agreement to establish her eligibility for matrix benefits. 
 Sellers additionally contends the pink form used to implement the accelerated 
implementation option formed a contract with AHP separate and apart from the 
settlement agreement, and that evidence she provided with the pink form should therefore 
be sufficient to establish her eligibility for matrix benefits.  Sellers’ argument suffers 
from two fatal flaws.  First, notwithstanding AHP’s decision to grant Sellers benefits 
under the accelerated implementation option, namely, a doctor’s visit and monetary 
compensation, the evidence she submitted failed to comply with the requirements of the 
pink form.  Sellers failed to provide adequate information and records specified by the 
pink form.  Moreover, she failed to complete the authorization for the trust to obtain her 
medical records.  Finally, she failed to provide a declaration from her prescribing 
                                                                                                                                                             
Univ. of Pittsburgh v. Champion Prods., 686 F.2d 1040, 1044 (3d Cir. 1982).  
Accordingly, the doctrine of laches is inapplicable to the facts Sellers alleges. 
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physician or the dispensing pharmacy.  Instead, she substituted affidavits from her 
husband and sister-in-law—insufficient proof under either the pink form or the settlement 
agreement. 
 Even assuming Sellers had provided adequate proof of ingestion under the pink 
form, by its plain terms, the pink form is not a stand-alone contract between AHP and 
Sellers.  The form explicitly states, “[t]he Settlement Agreement . . . is incorporated by 
reference into this Individual Agreement as if fully set out at length.”  As the arbitrator 
noted and the District Court affirmed, “[t]he Pink Form does not establish contractually 
any entitlement to Matrix Compensation Benefits. . . . [it] indicated Claimant’s 
acceptance of the Accelerated Implementation Option and registered an eligible Claimant 
for specified medical services, reimbursement of specified medical expenses, or fixed 
cash distributions.”  Even though the trust accepted Sellers’ proof for the purposes of the 
accelerated implementation option benefits, there was no contractual obligation for AHP 
to accept such proof for the purpose of evaluating eligibility for matrix benefits.  The 
District Court did not err in concluding the pink form did not modify or create any 
contractual obligation concerning eligibility for matrix benefits under the settlement 
agreement. 
 Accordingly, for the foregoing reasons, we will affirm the judgment of the District 
Court. 
